Outpatient Antibiogram 2023- Urine Source only

Gram Negative-Urine Only / Organisms	Aminoglycosides			Beta lactam/Beta lactam inhibitors				Carbapenems				Cephalosprin Class			Fluoroquinolones		Folate pathway inhibitor	Fosfomycin	Monobactams	Nitrofurans
	Amikacin	Gentamicin	Tobramycin	Amoxicillin/Clavulanate	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Meropenem	Cefazolin	Cefazolin Urine	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Fosfomycin	Aztreonam	Nirofurantoin
Citrobacter freundii complex (2)*		100	100	0	0	0	100	100	100	0			100	100	50	50	50			100
Enterobacter cloacae complex (10)*		100	100	0	0	0	100	100	100	0			100	90	100	100	80			0
Escherichia coli (180)		95	95	85	62	65	97	100	100		95		99	99	80	86	83			97
Escherichia coli, ESBL (13)*		76	76					100	100						7	15	30	92		92
Klebsiella oxytoca/Raoultella ornithinolytica (13)*		100	100	84	0	38	84	100	100	23			100	92	92	92	84			92
Klebsiella pneumoniae (32)		100	100	96	0	87	90	100	100		96		100	100	96	100	96			37
Klebsiella pneumoniae, ESBL (5)*		80	80					80	100						0	0	0			40
Klebsiella aerogenes (9)*		88	88	0	0	0	55	77	100				55	55	100	100	100			44
Proteus mirabilis (23)*		95	95	100	86	91	100	95			91		100	100	91	91	95			0
Pseudomonas aeruginosa (11)*	100	100	100				54		100			90	90		72	63			63	

Cefazolin predicts results for the oral agents-Cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil and loracarbef when used for therapy of uncomplicated UTI's due to E. coli, K. pneumoniae, and P. mirabilis.

*A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only. Interpret with caution.

COMMENTS:
1. Data are obtained from MIC and disk diffusion testing methods.
2. Isolate counts are in parenthesis to the right of the organism name.
3. MRSA (Methicillin Resitant Staph aureus):In 2023, 183 out 556 (32.9%) Staph aureus were MRSA.
 Prior years were as follows: 2022-30%, 2021-30.3%, 2020-30.0 %, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.
4. ESBL (Extended Spectrum Beta Lactamases): In 2023, 292 out of 3,279 (8.9%) were ESBL (combined inpatient and outpatient).
 Prior years were as follows: 2022-8.5%, 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
5. Penicillan Resistant Streptococcus pneumoniae: In 2023 no Penicillin Resistant Streptococcus pneumoniae.
Prior year were as follows: 2022, 2021 and 2020-No Penicillin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Outpatient Antibiogram 2023- Urine Source only

Gram positive-Urine only	Tetracycline	Ansamysins / Rifampin	Beta lactam/Beta lactam inhibitors / Ampicillin	Oxacillin	Cephalosprin Class / Cefazolin	Fluoroquinolones / Levofloxacin	Folate pathway inhibitor / Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Glycopeptides / Vancomycin IV	Lipopeptides / Daptomycin	Nitrofurans / Nitrofurantoin	oxazolidinones / Linezolid	Doxycycline	Ciprofloxacin	Clindamycin
Organisms														
Enterococcus faecalis (37)	16		100			97		100		100	100			
Staphylococcus epidermidis (5)*	100	100		60	60	75		100	100	100	100	100	100	100
Staphylococcus aureus (2)*	100	100		100	100	50	100	100	100	100	100	100		

*A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only. Interpret with caution.

COMMENTS:

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.

2. Isolate counts are in parenthesis to the right of the organism name.

3. MRSA (Methicillin Resitant Staph aureus):In 2023, 183 out 556 (32.9%) Staph aureus were MRSA.
 Prior years were as follows: 2022-30%, 2021-30.3%, 2020-30.0 %, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.

4. ESBL (Extended Spectrum Beta Lactamases): In 2023, 292 out of 3,279 (8.9%) were ESBL (combined inpatient and outpatient).
 Prior years were as follows: 2022-8.5%, 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.

5. Penicillan Resistant Streptococcus pneumoniae: In 2023 no Penicillin Resistant Streptococcus pneumoniae.

Prior year were as follows: 2022, 2021 and 2020-No Penicillin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Outpatient Antibiogram 2023-Non Urine Source only

Gram positive- Non Urine Only

Organisms	Tetracycline	Gentamicin Synergy Screen	Rifampin (Ansamysins)	Ampicillin (Beta lactam/Beta lactam inhibitors)	Oxacillin	Cefazolin	Ceftaroline (Cephalosprin Class)	Levofloxacin (Fluoroquinolones)	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole) (Folate pathway inhibitor)	Vancomycin IV (Glycopeptides)	Clindamycin (Lincosamides)	Daptomycin (Lipopeptides)	Erythromycin (Macrolides)	Linezolid (oxazolidinones)	Doxycycline	Ceftriaxone	Penicillin
Enterococcus faecalis (25)*		88		100						100		92		100			
Enterococcus faecium (1)*		100		100						100				100			
Staphylococcus epidermidis (6)*	33		100		16	16		50		100	83	100	0	100	33		
Staphylococcus aureus (54)	87		100		100	100	100	81	98	100	83	100	66	100	94		
Methicillin Resistant Staphylococcus aureus (19)*	73		100		0	0	94	10	88	100	52	100	10	100	94		
Streptococcus pneumoniae (2)*								100		100	50		0			100	100

*A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only. Interpret with caution.

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.

2. Isolate counts are in parenthesis to the right of the organism name.

3. MRSA (Methicillin Resitant Staph aureus):In 2023, 183 out 556 (32.9%) Staph aureus were MRSA.
 Prior years were as follows: 2022-30%, 2021-30.3%, 2020-30.0 %, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.

4. ESBL (Extended Spectrum Beta Lactamases): In 2023, 292 out of 3,279 (8.9%) were ESBL (combined inpatient and outpatient).
 Prior years were as follows: 2022-8.5%, 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.

5. Penicillan Resistant Streptococcus pneumoniae: In 2023 no Penicillin Resistant Streptococcus pneumoniae.

Prior year were as follows: 2022, 2021 and 2020-No Penicillin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Outpatient Antibiogram 2023- Non Urine Source only

Gram Negative -Non-Urine Only	Aminoglycosides			Beta lactam/Beta lactam inhibitors				Carbapenems				Cephalosprin Class		Fluoroquinolones		Folate pathway inhibitor	Monobactams
Organisms	Amikacin	Gentamicin	Tobramycin	Amoxicillin/Clavulanate	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Meropenem	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Aztreonam
Citrobacter freundii complex (4)*		100	100	0	0	0	100	100	100	0		100	100	75	75	75	
Enterobacter cloacae complex (8)*		100	100	0	0	0	87	100	100	0		87	87	100	100	100	
Escherichia coli (8)*		87	87	100	62	62	100	100	100	87		100	100	75	75	75	
Escherichia coli, ESBL (1)*								100	100								
Klebsiella pneumoniae (4)*		100	100	75	0	75	75	100	100	75		100	100	100	100	100	
Proteus mirabilis (9)*		88	88	100	88	88	100	88		0		88	88	77	77	77	
Pseudomonas aeruginosa (44)	100	100	95				95		97		97	95		79	79		86

*A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only. Interpret with caution.

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.

2. Isolate counts are in parenthesis to the right of the organism name.

3. MRSA (Methicillin Resitant Staph aureus):In 2023, 183 out 556 (32.9%) Staph aureus were MRSA.
 Prior years were as follows: 2022-30%, 2021-30.3%, 2020-30.0 %, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.

4. ESBL (Extended Spectrum Beta Lactamases): In 2023, 292 out of 3,279 (8.9%) were ESBL (combined inpatient and outpatient).
 Prior years were as follows: 2022-8.5%, 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.

5. Penicillan Resistant Streptococcus pneumoniae: In 2023 no Penicillin Resistant Streptococcus pneumoniae.
Prior year were as follows: 2022, 2021 and 2020-No Penicillin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.